Lonza
Lonza Group AG is globally recognized as a foundational and leading Contract Development and Manufacturing Organization (CDMO) in the healthcare industry, tracing its pioneering roots back to 1897 in Switzerland. It provides comprehensive, integrated services across the entire drug development pipeline, which distinguishes it as a full-service partner. In Pharmaceutical Contract Manufacturing, Lonza is critical in delivering Drug Substance/API Services, spanning high-quality small molecules, highly potent APIs (HPAPIs), and complex bioconjugates through its Advanced Synthesis segment. The company is a world leader in Biologics, offering end-to-end services in mammalian development and manufacturing, which is essential for monoclonal antibodies and recombinant proteins. Furthermore, Lonza is at the forefront of Specialized Modalities, supporting emerging technologies like mRNA, Cell & Gene Therapy (CGT), and microbial technologies. By combining cutting-edge science, smart technology, and lean manufacturing across its global network of approximately 19,000 employees, Lonza accelerates customers’ breakthrough innovations into viable, life-saving therapies, reinforcing its position as a strategic backbone for global biopharmaceutical production.
Latest Market Research Report on Pharmaceutical Contract Manufacturing Download PDF Brochure Now
Catalent, Inc.
Catalent is a leading global CDMO committed to accelerating the development, manufacturing, and delivery of products for pharma, biotech, and self-care companies. Known for its extensive network, deep expertise, and advanced proprietary technologies, the company positions itself as a champion for the missions of its customers. Catalent’s integrated CDMO solutions are expansive, covering the full product lifecycle from early-stage design through commercial manufacturing. Their core offerings are segmented into Oral Dose, Biologics, and Specialty, alongside comprehensive Clinical Supply Services. In pharmaceutical manufacturing, they specialize in complex drug delivery technologies, including softgel and oral dose formulations, blow/fill/seal sterile technologies, and advanced gene and cell therapy development and manufacturing. By ensuring seamless technology transfers, reliable outcomes, and the highest quality standards, Catalent plays a pivotal role in transforming bold ideas into life-changing therapies and self-care solutions, thereby improving health outcomes worldwide for patients and consumers.
Thermo Fisher Scientific Inc. (Patheon)
Thermo Fisher Scientific, a global giant in scientific solutions and healthcare, operates a powerful Pharmaceutical Contract Manufacturing business, largely consolidated under the Patheon brand, which it acquired to build a significant end-to-end CDMO presence. This integrated division provides comprehensive contract development and manufacturing services across the entire spectrum of pharmaceutical products. Their core services include the development and large-scale manufacturing of both drug substances—spanning biologics (such as proteins and vaccines) and small molecules (APIs)—and drug products in various dosage forms like sterile injectables, oral solid dose forms, and softgels. Leveraging Thermo Fisher’s expansive scientific expertise and global network of manufacturing sites, the CDMO division is able to ensure rapid technology transfer, scale-up, and reliable commercial supply. This integrated capability positions the company as a critical strategic partner for biopharmaceutical companies looking to accelerate their drugs from clinical stages through to global commercialization with consistency and high quality.
WuXi Biologics
WuXi Biologics is a world-leading Contract Development and Manufacturing Organization (CDMO) that specializes entirely in the rapidly growing field of biopharmaceuticals. As a dedicated biologics powerhouse, the company offers integrated, end-to-end services for the discovery, development, and manufacturing of biologics, which include monoclonal antibodies, recombinant proteins, and other complex biological products. WuXi Biologics employs a robust “follow-the-molecule” business model, providing flexible capacity and proprietary technology platforms to support clients from initial concept through to late-stage clinical trials and large-scale commercial production. Key services encompass cell line development, cell culture and process development, and clinical and commercial drug substance and drug product manufacturing, including sterile fill-finish. The company’s commitment to quality and speed, coupled with its massive biomanufacturing capacity in China and globally, has made it an essential partner for pharmaceutical companies seeking to accelerate the delivery of novel biopharmaceuticals to patients worldwide.
WuXi AppTec
WuXi AppTec is a global company that provides a comprehensive suite of R&D and manufacturing services, acting as a critical enabler for pharmaceutical, biotech, and medical device companies. In the Pharmaceutical Contract Manufacturing space, the company focuses heavily on small molecule drug development and manufacturing. It offers deeply integrated services that span from hit identification and lead optimization in drug discovery to preclinical development and clinical and commercial manufacturing. WuXi AppTec is a key provider of Active Pharmaceutical Ingredient (API) contract manufacturing, leveraging advanced chemistry and process technology platforms. Their CDMO services also extend to developing and manufacturing various dosage forms. By providing extensive capacity, rigorous quality control, and a geographically diverse operational footprint, WuXi AppTec enables its clients to streamline complex R&D processes, accelerate time-to-market, and reduce the overall cost of developing new chemical entities and generic drugs.
Samsung Biologics
Samsung Biologics is a prominent, pure-play biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, renowned for its massive-scale and high-quality biomanufacturing capabilities. The company has rapidly become a major global player, operating some of the largest single-site biomanufacturing plants in the world. Samsung Biologics offers comprehensive, end-to-end CDMO services for biopharmaceuticals, encompassing cell line development, process development, and manufacturing for both clinical and commercial supply. Their core expertise lies in the production of monoclonal antibodies and other biologics drug substances, complemented by integrated drug product (fill-finish) services. The company is strategically positioned to help global pharmaceutical companies manage supply chain risk and accelerate product delivery. By focusing on rapid technology transfer and ensuring global regulatory compliance, Samsung Biologics is essential in meeting the surging global demand for large-scale, high-quality biopharmaceutical manufacturing capacity.
Bora Pharmaceuticals Co., Ltd. & Corealis Pharma Inc. (Alliance)
This strategic alliance combines the strengths of a global commercial manufacturing leader, Bora Pharmaceuticals, and a leading early-phase Contract Development Manufacturing Organization (CDMO), Corealis Pharma Inc., to offer full end-to-end services, particularly in oral solid dose (OSD). The collaboration is designed to simplify and streamline the traditionally fragmented drug development and manufacturing pathway. Corealis contributes specialized expertise in early-phase activities, including formulation development and clinical-scale manufacturing. Bora provides the essential scale-up strength and global commercial infrastructure needed for Phase III and eventual market launch. By aligning project management and quality systems, the alliance effectively minimizes outsourcing risk for biotech and pharmaceutical innovators. This unified approach offers a clear, fast, and simple path from early-stage clinical work to seamless commercialization, accelerating the delivery of new medicines to patients reliably and efficiently across the globe.
US Specialty Formulations (USSF)
US Specialty Formulations (USSF) is a leading pharmaceutical contract manufacturer recognized for its commitment to quality, precision, and innovation, specializing in providing highly tailored solutions for asset-lite pharma companies. The company offers a comprehensive range of CDMO services designed to support drug development from the earliest preclinical stages through Phase II, regulatory applications, and commercial launch. USSF’s core expertise includes the development and manufacturing of small molecule formulations, sterile injectables, and specialty pharmaceuticals. They have a notable and extensive track record in handling complex formulations, such as sterile botanical formulations, while assisting clients in navigating intricate regulatory requirements. By providing customized formulations and an unwavering dedication to quality assurance and efficient production, USSF acts as a trusted partner for companies looking to bring their unique pharmaceutical visions to life with a high degree of specialization and hands-on expertise.
Altasciences
Altasciences is a contract development and manufacturing organization (CDMO) focused on simplifying drug development logistics to save time, reduce costs, and accelerate speed to market for pharmaceutical and biotech companies worldwide. The company provides a comprehensive suite of services that span drug development, manufacturing, and analytical testing, from early Phase I through large-scale commercial production. Their fully qualified, FDA-inspected facility supports a wide array of drug product manufacturing services, including formulation development, tablet manufacturing, liquid- and powder-filled capsules, and specialized techniques like wet nanomilling for challenging compounds. Altasciences is also capable of potent handling and producing blinded study materials (over-encapsulation). By integrating analytical services with manufacturing—including stability testing and the development and validation of critical methodologies—Altasciences ensures a seamless and efficient transition from the clinical supply stage to final commercial manufacturing.
UPM Pharmaceuticals
UPM Pharmaceuticals is an independent, family-owned Contract Development and Manufacturing Organization (CDMO) that has built a strong reputation and commercial pedigree as a supplier to Big Pharma, having advanced over 80 compounds from concept to commercialization. The company specializes in the production of semi-solid and solid dose drug products. A core strength of UPM lies in late-stage commercial pharmaceutical manufacturing, where they excel in technology transfer and scale-up support, handling hundreds of millions of doses annually. Their pharmaceutical services are comprehensive, including formulation, analytical, microbial, and stability testing. Furthermore, UPM is highly specialized in managing intricate processes involving potent handling, hormones, and DEA-licensed controlled substances. By combining a legacy of know-how with customized pharmaceutical development services from its dedicated facility, UPM serves as a reliable CDMO partner for clients seeking to propel their products efficiently and safely toward market success.
Latest Market Research Report on Pharmaceutical Contract Manufacturing Download PDF Brochure Now